Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X
Metrics: PDF 350 views | Full Text 1209 views | ?
Reiko Yoshida1,2, Chie Watanabe2,3, Shiro Yokoyama2, Mayuko Inuzuka2, Junko Yotsumoto2, Masami Arai1, Seigo Nakamura2,4 and the Registration Committee of the Japanese HBOC consortium
1 Division of Clinical Genetic Oncology, Cancer Institute Hospital, Tokyo, Japan
2 Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
3 Department of Nursing, Faculty of Human Sciences, Sophia University, Tokyo, Japan
4 The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
Keywords: hereditary breast and ovarian cancer; BRCA1; founder mutation; L63X; c.188T>A
Abbreviations: HBOC: hereditary breast and ovarian cancer syndrome; BCCR: breast cancer cluster regions
Received: December 08, 2018 Accepted: March 23, 2019 Published: May 14, 2019
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.